TargTex

Another awake call from Vincent Ling highlighting how hydrogel-based systems can transform patient's lives and impact on blockbuster drugs. Sustained drug release translates into increased patient compliance and reduced side effects. Let's hope these positive trends may entice investors and pharma engagement to fully enable these technologies. At TargTex we are working to validate our localized sustained delivery approaches in the clinics.

July 17th 2024. Today is the Glioblastoma Awareness Day. GBM is the most common and aggressive type of brain cancer, affecting thousands of patients and their families worldwide. Today we send a message of hope, courage and solidarity for those affected by GBM and state that at TargTex we are committed to bring our innovative solution to the clinics and offering these patients a real chance to fight this disease. #GBMDay

Happy Birthday TargTex! Today we celebrate our 5th anniversary. It has been a challenging and rewarding journey. We can only say THANK YOU to all our collaborators, investors, partners and colleagues who have supported us through this journey and have made it possible to bring our solution closer to the patients in need. We are now a small step away from delivering our product to #Glioblastoma patients and ready to address other challenging unmet medical needs. Thank you all for your support

Last week our CEO João Seixas and COO Pedro M.S.D. Cal attended 5th Annual Glioblastoma Drug Development Summit. Once again, a privileged opportunity to meet with key opinion leaders and patient advocates and also to network with companies working in this space and discuss the best strategies to develop new medicines for #glioblastoma patients.

Today was the last day of #BioEurope Spring 2024 in Barcelona. During these last days we had the opportunity to reach out to investors and explain how we're developing selective drugs to address high unmet medical needs. We still had time to meet partners and engage with the local medical community that will help us bring our innovative treatment to #glioblastoma patients.

A great partnership with Nanoform!

TargTex reaches another important milestone: We are proud to announce that our product TTX101 was granted Orphan Drug Designation (#ODD) by the Food and Drug Administration (#FDA) in the USA, for the treatment of malignant #gliomas, such as Glioblastoma (#GBM). Looking forward to take our treatment to patients in need! Check our press release at: https://lnkd.in/dGbkwXGU